Since we have no income it's best to
try to consider using an alternative like
EV/invested in R&D pipelines or by using EV/comparative M&A for basic cost-based valuation. At this stage what suited for us is using comparative methods. This is one of the most popular method publicly used. You can also find the good Dr using this type of methodology by comparable in the latest M&A transactions. IMO now we have DX1 and DX3 with on coming news 10c are achievable IMO. Don't forget it could be way over 10c if big pharma have appetites for early stage companies like ours.
PAB Price at posting:
2.3¢ Sentiment: Hold Disclosure: Held
